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Adenosine-Thallium Imaging :
Faster and Better?*
FRANS J . TH . WACKERS, MD . FACC
New Haven, Connecticut
Dipyridamole-thallium-20l imaging. Since the early
1980s dipyridamole-thallium-201 imaging has become a rou-
tine procedure in many nuclear cardiology laboratories (I-
4). Patients incapable of exercising on a treadmill or bicycle
because of orthopedic, neurologic or peripheral vascular
disease can be evaluated effectively for the presence of
significant coronary artery disease with the use of dipyrida-
mule-thallium imaging
. Extensive clinical experience has
shown that this noninvasive procedure is relatively safe (5-7)
and provides diagnostic and prognostic information compa-
rable to that derived by exercise thallium imaging 11,2,8-16)
.
Nevertheless, for unclear reasons, intravenous dipyridamole
has not as yet been approved for this clinical application by
the Food and Drug Administration .
Intravenous dipyridamole causes selective vasodilation
of the coronary resistance vasculature . In patients with
significant coronary artery disease this results in regional
heterogeneity of myocardial blood flow that can be imaged
with thallium-201 (17). The vasodilative action of dipyrida-
mole is the indirect result of elevation of endogenous aden-
osine levels by blocking reentry of adenosine across the cell
membrane (18-20) .
Although intravenous dipyridamole-thallium imaging has
proved its clinical usefulness, the degree of vasodilation
achieved by dipyridamole may vary in individual patients .
Homma et al, (21) demonstrated a relatively wide range in
serum dipyridamole levels after intravenous administration .
Maximal pharmacologic effect occurs approximately 4 min
after completion of infusion and is maintained for approxi-
mately 20 to 40 min. This relatively prolonged effect poses a
potential problem in patients who experience adverse reac-
tions. Usually these side effects can be reversed readily by
intravenous aminophyline (22,231 ; however, because of the
'Editorials published in Jonrnol of
rlre American College of Cardiology
once, the views of
the authors and do not necessarily represent the views of
JACC a
: the American College of Cardiology .
From the Cardiovascular Nuclear Imaging and Exercise laboratories .
Donsamems of Medicine (Cardiology) and Diagnostic Radiology (Nuclear
Med
:cine), Yale University School of Medicine, New Haven, Connecticut .
Add-to,reprints: Frans 1 . Th . Wackers . MD. FACC . Yale University
School of Medicine . Cardiovascular Nucear Imaging Iaharatory . 331 Cedar
Street, TE-2 New Haven, Connecticut 06510.
01990 by the American College crCardiology
JACC Vol. 16. No. 6
November 15. 1990 :1384-6
prolonged effect of dipyridamole, at times symptoms may
recur after an initial favorable response.
Adennsine-thallium-201 imaging. Because of the limited
availability of dipyridamole for this application (one needs a
physician's Investigational New Drug number issued by the
Food and Drug Administration), alternative pharmacologic
approaches to achieve coronary vasodilation, such as the
use of papaverine or nitroglycerin, have been explored .
Recently, intravenous infusion of adenosine has been pro-
posed as a means of achieving directly what is an indirect
effect of dipyridamole (24). Adenosine is a potent fast-acting
endogenous coronary vasodilator that relaxes vascular
smooth muscle by either inhibition of the slow inward
calcium current or activation of adenylate cyclase (25). It is
quickly metabolized in red blood cells, which accounts for
its short half-life .
Two particularly attractive aspects of adenosine for clin-
ical pharmacologic vasodilation are its rapid onset of action
and extremely short half-life . Wilson et al. (26) demonstrated
a near (4.5 times) maximal increase in coronary blood flow at
120 s after the start of infusion of adenosine . Coronary flow
returned rapidly to baseline at 113 s after termination of the
infusion. In contrast, with the use of dipyridamole the
increase of myocardial blood flow occurs more gradually, is
generally less in magnitude and is more variable. Maximal
increase in coronary blood flow is not achieved in all patients
(27) .
The present study. In this issue of the Journal, Nguyen et
al. (28) report on the feasibility, safety and diagnostic
accuracy of adenosine-thallium single photon emission com-
puted tomographic (SPECT) imaging . Although the number
of patients studied was relatively small (53 patients with and
7 patients without coronary artery disease), the diagnostic
accuracy of adenosine-thallium imaging was comparable to
that of exercise thallium imaging
. Of particular interest are
the observations in the subgroup of patients who also had
two-dimensional echocardiography. During adenosine infu-
.,ion only 2 of these patients had echocardiographic regional
wall motion abnormalities, whereas 16 of 20 patients had
reversible thallium perfusion defects. Assuming that adeno-
sine achieved maximal coronary vasodilation, these obser-
vations can be compared with those of Picano et al . (29),
who performed high dose dipyridamole echocardiography .
The observations of Nguyen et al
. (28) indicate that tballium-
201 perfusion abnormalities occur more frequently and may
occur without associated echocardiographic regional wall
motion abnormalities . These findings imply that adcnosine-
induced heterogeneity of blood flow often does
not result in
myocardial ischemia.
The results of Nguyen et al . (28) are comparable with
those published recently by Verani et al, (30) . Employing
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Table 1 . Reported Side Effects (713 of patients) of Inimvenous
Dipyridamole-and Adenosine-Thallium imaging
'Patients with history of bronchospasm excluded . AV = auiovenlriwlara
ECG=eteetroeardioueam
;MI= myocardialint otion_
incremental infusion doses of adenosine and thallium-201
SPECT imaging, the latter investigators reported an overall
sensitivity of 83% and a specificity of 94% for detecting
angiographic coronary artery disease in 57 patients .
Both the study of Verani et al . (30) and that of Nguyen et
al. (28) report a relatively high incidence of side effects : 88%
and 83%, respectively, In general, these adverse reactions
were reported to be mild and were usually resolved within I
to 2 min after termination of adenosine infusion . In compar-
ison, the reported incidence of side effects of 35% with
dipyridamole infusion is considerably lower. In particular .
chest, throat or jaw pain occurred more frequently with the
administration of adenosine than of dipyridamole (Table I) .
An adverse effect that has attracted much attention and has
raised considerable concern is the occasional occurrence of
high degree atrioventricular block . However, this complica-
tion is infrequent and is resolved promptly after discontinu
ation of adenosine infusion . No patients in the current study
needed placement of a temporary pacemaker .
Adenosine versus dipyridamole-thallium Imaging . Ade-
nosine-infusion is an attractive alternative for pharmacologic
vasodilation in combination with thallium-20t imaging be-
cause of its fast onset of action, near maximal coronary
vasoditation and short half-life. These favorable character-
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istics may allow a more consistent pharmacologic effect in all
patients than is achieved with dipyridamole .
The diagnostic and prognostic significance of abnormal
dipyridamole-thallium studies has been well documented
III-16.311 . There is no reason to believe that adenosine-
thallium-201 imaging would he any less effective . The recent
reported results (28,30) are extremely promising, The rela-
tively high incidence of side effects is of concern and should
he evaluated in a larger number of patients with a broader
range of clinical presentations of coronary disease . The short
half-life makes it possible to quickly adjust the dose of
adenosine infusion and control potentially serious adverse
reactions. Further clinical experience should also clarify
whether the two compounds can be employed interchange-
ably or whether in certain patient groups one is preferred
aver the other .
Combination with newer imaging agents- Adenosine may
be particularly suited for use with the recently developed
new technetium-99m-labeled myocardial perfusion imaging
agents . For instance, technetium-99m teboroxime is a myo-
cardial perfusion imaging agent with markedly differrt
choeacteristics from those of thallium-201 . After initial accu-
mulation according to the distribution of myocardial blood
flow, it is cleared from the heart within 3 to 4 min (32) .
.Adenosine infusion would allow appropriate timing of injec-
tion of technetium-99m teboroxime at maximal coronary
vasoditation
. Furthermore, the short half-life of adenosine,
as well as the rapid clearance of technetium-99m leborox-
ime, would make it possible to perform repeat studies within
a short time .
In contrast, another new imaging agent, technetium-99m
methoxy-isohutyl isenitrile (SestsMIM), remains "fixed
-" in
the heart for a number of hours after initial distribution
according to myocardial blood flow
(33).
Imaging usually is
performed 40 to 60 min after injection . Repeat imaging can
be performed several hours later or on a different day .
Neither dipyridamole nor adenosine would seem preferable
to this new agent .
Conclusions. Pharmacologic vasoditation-myocardial
perfusion imaging has become an important and useful
alternative to exercise testing
. It is to be hoped that the
accumulated evidence of clinical safety may prompt the
Food and Drug Administration to approve these compounds
for this application in the very near future .
The,cclct,inal ussisrancc of bare Counmanebe
is greatly appreciated .
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